Jason Philip Van Batavia
VerifiedUniversity of Pennsylvania · Rehabilitation Medicine
Active 2007–2025
About
Jason Philip Van Batavia, MD, is an Associate Professor of Surgery at the Children's Hospital of Philadelphia, specializing in Urology. He is an attending physician in the Division of Urology at the Children's Hospital of Philadelphia in Philadelphia, PA. Dr. Van Batavia completed his undergraduate studies in Molecular Biophysics and Biochemistry at Yale University in 2005. He earned his MD from Columbia University College of Physicians and Surgeons in 2009. Furthering his expertise, he obtained a Master of Science in Translational Research from the University of Pennsylvania in 2021, through the Institute for Translational Medicine and Therapeutics. His professional focus includes pediatric urology, with research contributions in adolescent varicocele, urinary tract infections, ureteropelvic junction obstruction, hypospadias repairs, bladder dysfunction in children with spina bifida, and neurogenic bladder and bowel management. Dr. Van Batavia has authored multiple publications in these areas, emphasizing surgical outcomes, risk stratification, and innovative treatment approaches. His work is recognized for its clinical relevance and contribution to improving pediatric urological care.
Research topics
- Surgery
- Radiology
- Internal medicine
- Medicine
Selected publications
Inflammatory Myofibroblastic Tumor of the Bladder in Childhood: A Three Case Series
Urology · 2025-03-04 · 3 citations
articleThe Journal of Urology · 2025-03-25 · 4 citations
articleOpen accessPURPOSE: Variability in the interpretation of videourodynamics studies limits reliable classification of kidney injury risk for patients with spina bifida. We developed machine learning models to predict incident hydronephrosis in patients with spina bifida using videourodynamics data. MATERIALS AND METHODS: We trained machine learning models using data from videourodynamics studies performed between 2016 and 2022 on patients with spina bifida aged 2 months to 42 years. We evaluated the performance of 4 models to predict incident hydronephrosis following an index videourodynamics study: (1) random survival forest model using data prospectively abstracted from videourodynamics studies by urologists, (2) random survival forest of bladder volume-pressure data, (3) random survival forest using deep learning features extracted from fluoroscopic images of the bladder, (4) ensemble model averaging the probabilities of the volume-pressure and fluoroscopic models. RESULTS: We included 354 and 200 patients in the training and validation cohorts, respectively. Among the training and validation cohorts, 89 (25.1%) and 71 (35.5%) patients developed incident hydronephrosis at a median time of 1.6 (IQR, 0.5-3) and 2.49 (IQR, 1.72-3.03) years after the index videourodynamics study, respectively. The ensemble model that included data from studies during which ≥ 75% expected bladder capacity was reached had the best discrimination (C statistic 0.73; 95% CI, 0.68-0.76). The specificity of high-risk scores (top 10% in the ensemble model) was 97%. CONCLUSIONS: Automated extraction of features from pressure/volume recordings and fluoroscopic images of the bladder predicted incident hydronephrosis in patients with spina bifida.
MP26-12 LONG-TERM FUNCTIONAL OUTCOMES AFTER CLOACA RECONSTRUCTION
The Journal of Urology · 2025-04-08
articleThe Journal of Urology · 2025-10-10
articlePURPOSE: This study evaluates the clinical characteristics and predictors of febrile UTI (fUTI) in children with potentially persistent primary vesicoureteral reflux (VUR) who discontinued continuous antibiotic prophylaxis (CAP) without radiographic confirmation of reflux resolution. We hypothesize that many patients can safely discontinue CAP after toilet training and that a nomogram can predict the probability of fUTI after cessation. MATERIALS AND METHODS: A retrospective review of an institutional VUR registry (2012-2018) identified children managed with CAP who subsequently discontinued prophylaxis. Patients with secondary VUR, underlying anatomic abnormalities, or inadequate follow-up were excluded. Demographics, clinical characteristics, and outcomes were analyzed. Multivariable Cox proportional hazards modeling identified predictors of postcessation fUTI, and a nomogram was constructed. Model performance was evaluated using the concordance index (C index) and time-dependent AUC (area under the ROC curve). A simplified clinical risk score was developed and validated. RESULTS: < .001). CONCLUSIONS: CAP discontinuation is a viable strategy in select children with persistent VUR, particularly those without voiding dysfunction. A predictive nomogram provides a valuable tool for individualized decision-making. Prospective studies are warranted to refine risk stratification and optimize management strategies.
JMIR Research Protocols · 2025-04-04 · 1 citations
articleOpen accessBACKGROUND: According to International Children's Continence Society, the first-line treatment of children with daytime urinary incontinence is standard urotherapy, eventually followed by pharmacotherapy of anticholinergics. The effect of medical treatment is sparsely investigated and has been investigated primarily in nonrandomized trials. OBJECTIVE: The primary objective of this trial is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in the treatment of daytime urinary incontinence among children aged 5-14 years who are noncomplete responders to monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose. The secondary objective is to evaluate the treatment response of combination therapy of solifenacin and mirabegron in low doses, monotherapy in high doses, and monotherapy in low doses as supplementary comparisons. Additionally, the secondary objective is to evaluate the side effects, safety, and tolerability of the medical treatment as well as the effect of the treatment on the well-being and quality of life. METHODS: Children aged 5-14 years diagnosed with daytime urinary incontinence refractory to standard urotherapy will be randomized 1:1:1:1 to 4 treatment groups. Initially, 2 groups will receive solifenacin 5 mg and 2 groups will receive mirabegron 25 mg. After 6 weeks, noncomplete responders will receive add-on treatments according to their primary randomization group. Group 1A will receive solifenacin 5 mg and add-on solifenacin 5 mg, group 1B will receive solifenacin 5 mg and add-on mirabegron 25 mg, group 2A will receive mirabegron 25 mg and add-on mirabegron 25 mg, and group 2B will receive mirabegron 25 mg and add-on solifenacin 5 mg. The total treatment period will be 18 weeks. The primary end point measure is treatment response assessed by change from visit 2 to the end of the study, according to the number of wet days per 7 days by DryPie. RESULTS: The BeDry study was approved by Clinical Trials in the European Union on June 12, 2024. Recruitment began on June 27, 2024, and will continue until 236 patients are included, which is expected to occur by September 2026. As of April 2025, 75 participants are included. CONCLUSIONS: This trial has the potential to optimize the medical treatment of children with daytime urinary incontinence, shorten the treatment period, diminish the side effects, and minimize unnecessary medical expenses. TRIAL REGISTRATION: Clinical Trials in the European Union EUCT 2023-510187-13-00; https://tinyurl.com/2hva7ph8; ClinicalTrials.gov NCT06551246; https://clinicaltrials.gov/study/NCT06551246. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/63588.
Neurourology and Urodynamics · 2025-08-25 · 1 citations
articleOpen accessOBJECTIVES: To (1) propose standardized terminology for bladder shapes on fluoroscopic images in a pediatric spina bifida population and (2) determine if bladder shape is associated with filling pressures and other measures of bladder dysfunction. We hypothesized that oblong, trabeculated, and "Christmas tree" bladders would have higher filling pressures and worse bladder function (higher filling pressures; higher presence of vesicoureteral reflux, leakage, detrusor-external sphincter dyssynergia, and hydronephrosis) than smooth and round-shaped bladders. METHODS: We conducted a cross-sectional study of pediatric and adolescent patients with spina bifida who underwent video urodynamics (VUDS) at a tertiary center from July 2016 to June 2022. Representative fluoroscopic bladder images from the earliest available VUDS were categorized by unsupervised cluster analysis. Five urologists also determined standardized classifications for bladder shape (round, oblong, and "Christmas tree") and contour (smooth or trabeculated/diverticulated), which were applied to the bladder images. Bladder filling pressures and clinical measures of bladder function were compared among bladder shapes. RESULTS: Four hundred seventeen patients with a median age of 2.6 years (IQR 0.4-8.0 years) were included. For the machine learning cluster analysis of bladder shape, clusters with more trabeculated-appearing bladders had higher filling pressures. For expert clinician classification, round trabeculated, oblong trabeculated, and "Christmas tree" bladders had higher filling pressures than round smooth and oblong smooth bladders, a difference that was statistically significant. Statistically significant differences were noted among bladder shapes for the presence of vesicoureteral reflux, leakage, detrusor-external sphincter dyssynergia, and hydronephrosis. Moderate and severe bladder dysfunction were present across all bladder shape clusters. CONCLUSIONS: We established a standardized bladder shape nomenclature in children and adolescents with spina bifida. Higher bladder filling pressures are associated with trabeculations and "Christmas tree" appearance versus smooth contour, but not oblong versus round shape. Bladder shape alone does not appear to consistently differentiate the presence of hydronephrosis, vesicoureteral reflux, leakage, detrusor-external sphincter dyssynergia, or bladder dysfunction severity.
The Journal of Urology · 2025-06-09
erratumJournal of Pediatric Urology · 2025-05-07 · 6 citations
articleJournal of Pediatric Urology · 2025-01-01 · 1 citations
articleJMIR Research Protocols · 2025-04-04
articleOpen accessBACKGROUND: To the best of our knowledge, no studies have investigated the withdrawal strategy of pharmacological treatment with solifenacin or mirabegron in children diagnosed with urinary incontinence who have achieved continence on pharmacotherapy. OBJECTIVE: The primary objective is to investigate if abrupt withdrawal versus gradual withdrawal of pharmacotherapy (solifenacin or mirabegron) influences the risk of recurrence of incontinence, assessed by a self-reported 14-day calendar of incontinence episodes. METHODS: Children aged 5-14 years diagnosed with urinary incontinence, treated with pharmacotherapy of solifenacin or mirabegron and ready for withdrawal, will be randomized 1:1 to either abrupt or gradual withdrawal, according to the medical treatment that the child is receiving. The primary outcome measure is the recurrence of incontinence after withdrawal, 1 month after initiation of withdrawal of the physician-prescribed medication, assessed by a self-reported 14-day calendar of incontinence episodes. In addition, recurrence of incontinence after 3, 6, and 12 months after initiation of withdrawal will be measured. The hypothesis that gradual withdrawal is superior to abrupt withdrawal regarding the risk of recurrence of incontinence will be analyzed by logistic regression. RESULTS: Recruitment began at the end of May 2024 and will continue until 216 patients are included, which is expected by December 2027. As of February 2025, a total of 25 participants are included. CONCLUSIONS: The results are expected to influence the withdrawal strategy of pharmacological treatment with solifenacin or mirabegron in children with daytime urinary incontinence. TRIAL REGISTRATION: ClinicalTrials.gov NCT06465576; https://clinicaltrials.gov/search?term=NCT06465576. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/63226.
Recent grants
Frequent coauthors
- 112 shared
Kenneth I. Glassberg
Columbia University Irving Medical Center
- 84 shared
Andrew J. Combs
Boston Children's Hospital
- 71 shared
Christopher Long
Children's Hospital of Philadelphia
- 64 shared
Dana A. Weiss
- 62 shared
Thomas F. Kolon
- 59 shared
Stephen A. Zderic
- 56 shared
Aseem R. Shukla
Children's Hospital of Philadelphia
- 53 shared
Arun K. Srinivasan
University of Pennsylvania
Education
- 2009
MD
Columbia University College of Physicians and Surgeons
- 2005
BS
Yale University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Jason Philip Van Batavia
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup